Skip to main content
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 2007 Aug;149(2):399. doi: 10.1111/j.1365-2249.2007.03465.x

Corrigenda

PMCID: PMC1941945

In [1], IL-1β is erroneously named IL-1α on several occasions in the text.

IL-1β is used correctly in the abstract (p. 168) and in the relevant figure heading (Fig 5a, p. 173).

IL-1α is incorrectly used on seven (7) occasions throughout the paper:

  • p 169, Top left column (Introduction), line 3.

  • p 171, Bottom right column (Results), line 40.

  • p 172, Bottom right column (Results), line 1.

  • p 173, Bottom right column (Results), line 4.

  • p 173, Figure legend, figure 5.

  • p 175, Center left column (Discussion), line 26.

  • p 175, Top right column (Discussion), line 3.

IL-1α should be substituted with IL-1β in all these occurrences.

In [1], an extra comma was introduced in the keywords list: ‘multiple organ dysfunction, syndrome (MODS)’. This is incorrect and should read ‘multiple organ dysfunction syndrome (MODS)’.

We apologize for these errors.

Reference

  • 1.Sandvik A, Wang YY, Morton HC, Aasen AO, Wang JE, Johansen F-E. Oral and systemic administration of β-glucan protects against lipopolysaccharide-induced shock and organ injury in rats. Clin Exp Immunol. 2007;148:168–177. doi: 10.1111/j.1365-2249.2006.03320.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES